- Associated Press - Monday, October 25, 2010

FLAT VICTORY: Biotech drugmaker Amgen Inc. said Monday its third-quarter profit fell because of flat sales and higher operating costs, although the drugmaker still beat expectations.

ANEMIC SALES: Lower sales of the company’s best-selling anemia drugs were offset by higher Neulasta and Neupogen sales. The drugs are used to help prevent infections in chemotherapy patients.

BONE DRUG: Sales of the company’s newest drug Prolia were underwhelming at $10 million. The drug, approved as a treatment for postmenopausal women at risk for fractures, is seen as a key revenue driver for company growth.


Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide